Effect of Neostigmine on the Recovery of Rocuronium: A Comparison Between Partial and TOF Ratio-Based Dose

Sponsor
Indonesia University (Other)
Overall Status
Completed
CT.gov ID
NCT03058263
Collaborator
(none)
66
1
2
4.9
13.4

Study Details

Study Description

Brief Summary

This study aimed to evaluate the effect of Neostigmine partial dose towards neuromuscular blockade of rocuronium

Condition or Disease Intervention/Treatment Phase
  • Drug: Dose of Neostigmine
Phase 1/Phase 2

Detailed Description

Approval from Ethical Committee of Faculty of Medicine University of Indonesia was acquired prior conducting the study. Subjects were given informed consent before enrolling the study and randomized into two groups. Intravenous (IV) cannula with Ringer Lactate fluid, non-invasive blood pressure monitor, electrocardiogram (ECG) and pulse-oxymetry were set on the subjects in the operation room. After preoxygenation was given with 100% oxygen, general anesthesia induction was done with midazolam 0.01-0.02 mg/kg, fentanyl 3 mcg/kg, propofol 1-2 mg/kg, and rocuronium 0.6 mg/kg. Following induction, endotracheal intubation or laryngeal mask insertion was performed. Maintenance was done by sevoflurane 1.2 vol%, and fentanyl 1.2 mcg/kg. After the surgery had finished, fentanyl drip was stopped. Subjects were then observed until spontaneous breaths occured adequately (tidal volume ≥ 5 ml/kg) before train of four (TOF) ratio was evaluated using acceleromyography (AMG). Before reversal (neostigmine) was given, anesthetic gas was stopped and duration of operation as well as post-operative TOF ratio was recorded. The time since reversal was given then recorded. Group A received neostigmine partial dose (0.02 mg) in combination with atropine 0.4 mg for every milligram of neostigmine. Group B received TOF ratio-based dose of neostigmine in combination with atropine 0.4 mg for every milligram of neostigmine. After administration of neostigmine, TOF ratio was measured every 5 minutes until TOF ratio of ≥ 90% was achieved, and finally definitive airway could be removed. For Group A, another partial dose of neostigmine was given after 10 minutes from the first reversal dose if the TOF ratio of ≥90% had not been reached. For Group B, another TOF ratio-based dose of neostigmine was given after 10 minutes from the first reversal dose if the TOF ratio of ≥90% had not been reached. Subjects were then transported to recovery room. Data was analyzed using Statistical Package for the Social Sciences (SPSS), for numerical data using unpaired T-test or Mann-Whitney-U test, for categorical data using Chi-square test or Fischer Exact's Test. Data normality was tested by Kolmogorov-Smirnov test. Significant value is p<0.05.

Study Design

Study Type:
Interventional
Actual Enrollment :
66 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
The Effectiveness of Neostigmine on the Recovery of Rocuronium-Induced Neuromuscular Blockade: A Comparison Between Partial Dose and TOF Ratio-Based Adjustment Dose
Actual Study Start Date :
Oct 1, 2016
Actual Primary Completion Date :
Feb 1, 2017
Actual Study Completion Date :
Feb 28, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: partial dose of neostigmine

Those who received partial dose of neostigmine as rocuronium reversal

Drug: Dose of Neostigmine
Subjects were given partial dose of neostigmine as rocuronium reversal after the surgery had finished; subjects were given TOF ratio-based dose of neostigmine after the surgery had finished
Other Names:
  • prostigmin
  • Experimental: TOF ratio-based dose of neostigmine

    Those who received TOF ratio-based dose of neostigmine as rocuronium reversal

    Drug: Dose of Neostigmine
    Subjects were given partial dose of neostigmine as rocuronium reversal after the surgery had finished; subjects were given TOF ratio-based dose of neostigmine after the surgery had finished
    Other Names:
  • prostigmin
  • Outcome Measures

    Primary Outcome Measures

    1. TOF ratio with partial dose of neostigmine [Day 1]

      Train-of-Four ratio obtained from post-operative acceleromyography after the first partial dose of neostigmine had been administrated until definitive airway device can be removed

    2. TOF ratio with TOF ratio-based dose of neostigmine [Day 1]

    3. TOF ratio between partial dose of neostigmine and TOF ratio-based dose of neostigmine [Day 1]

    4. time needed to reach TOF ratio ≥ 90% in group with partial dose of neostigmine [Day 1]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 60 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • patients aged 18-60 years old

    • American Society of Anesthesiologists (ASA) physical status I-II who were planned to undergo any elective surgery at operating room in general anesthesia

    • subjects had been explained about the study, and agreed to enroll and have signed the informed consent form

    Exclusion Criteria:
    • BMI ≥ 30

    • had any severe kidney or liver disease

    • had neuromuscular disease or asthma

    Drop out Criteria:
    • Duration of operation less than one hour or more than 2 hours

    • during surgery received maintenance dose of neuromuscular block

    • intraoperative cardiac arrest was occurred

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cipto Mangunkusumo Cental National Hospital Jakarta DKI Jakarta Indonesia 10430

    Sponsors and Collaborators

    • Indonesia University

    Investigators

    • Principal Investigator: Arif HM Marsaban, Consultant, Indonesia University

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    Responsible Party:
    Arif H. M. Marsaban, Anesthesiologist Consultant, Indonesia University
    ClinicalTrials.gov Identifier:
    NCT03058263
    Other Study ID Numbers:
    • IndonesiaUAnes011
    First Posted:
    Feb 20, 2017
    Last Update Posted:
    Aug 18, 2017
    Last Verified:
    Aug 1, 2017
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 18, 2017